Dysthyroid Optic Neuropathy Thyroid Eye Disease Optic Neuropathy Graves Ophthalmopathy Thyroid Eye Disease Methylprednisolone Orbital Decompression Radiation Therapy Immunosuppressive Agents
Conditions
Interventions
All Participants who received intravenous corticosteroid treatment as the primary management for dysthyroid optic neuropathy.,Participants who received orbital decompression surgery as treatment for d
IV Steroid Therapy,Orbital Decompression Surgery,Radiotherapy ,Immunosuppressive Therapy
Sponsors
Mettapracharak (Wat Rai Khing) Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients diagnosed and treated for dysthyroid optic neuropathy (DON) at least one year prior to enrollment. Age 18 years or older.
Exclusion criteria
Exclusion criteria: Patients with vision loss caused by other ocular diseases, such as cataract, severe corneal opacity, optic nerve disorders unrelated to DON, retinal diseases, or any condition that may confound the assessment of optic nerve function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity at 12 months after treatment Measured using Snellen chart and converted to logMAR for analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Optic nerve function within one year after treatment Evaluation of color vision, relative afferent pupillary defect | — |
Countries
Thailand
Contacts
Public ContactTanunya Pimma
Department of Ophthalmology, Metta Pracharak Hospital
Outcome results
None listed